In recent years, Immunotherapy has become one of the most attractive treatment modalities for cancer. Most of the first-generation cancer immunotherapy drugs were antibody-based checkpoint inhibitors such as Anti-PD1 and Anti-CTLA4, however, in recent years small molecule modulators of the immune system are gaining prominence due to several advantages such as potential for oral administration and the ability to modulate intracellular targets. While several small molecules are in clinics or under development for modulating targets of existing biological drugs such as PD1/PDL1 interaction inhibitors, there are also several more in development targeting novel targets such as STING modulators, TLR agonists, etc. Small molecule modulators of the immune system are hence demonstrating promise for the treatment of oncology and fast becoming extremely attractive therapeutic modalities.
Immunotherapy is one of the most attractive treatment modalities in medicine today, however research in this area and the translation to clinic is largely focused on biologicals such as monoclonal antibodies, cell therapy, etc. Small molecules modulators of the immune system have the potential to overcome challenges faced by biological drugs and also complement them for improving treatment efficacy. The goal of this special issue would be to bring attention to the latest advances in small molecule modulators of the immune system for treatment of cancer and infectious diseases.
We welcome Original Research, Review, Mini Review and Perspective articles on themes including, but not limited to:
• Discovery and design of novel small molecules and peptides
• Lead optimization and structure-activity relationship studies
• Applications of small molecule and peptide based therapeutics for immunotherapy of cancer
• Chemical probes and chemical biology studies for new targets in immunotherapy
Topic Editor Dr. Aditya Kulkarni is the founder and CSO of Avammune Therapeutics and Aten Porus Lifesciences. Topic editor Dr. Madduri Srinivasarao is currently serving as the Vice President of R&D at Eradivir, Inc. and serves as a consultant at Morphimmune Inc. and Umoja Biopharma Inc. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation are considered out of scope of this section.
In recent years, Immunotherapy has become one of the most attractive treatment modalities for cancer. Most of the first-generation cancer immunotherapy drugs were antibody-based checkpoint inhibitors such as Anti-PD1 and Anti-CTLA4, however, in recent years small molecule modulators of the immune system are gaining prominence due to several advantages such as potential for oral administration and the ability to modulate intracellular targets. While several small molecules are in clinics or under development for modulating targets of existing biological drugs such as PD1/PDL1 interaction inhibitors, there are also several more in development targeting novel targets such as STING modulators, TLR agonists, etc. Small molecule modulators of the immune system are hence demonstrating promise for the treatment of oncology and fast becoming extremely attractive therapeutic modalities.
Immunotherapy is one of the most attractive treatment modalities in medicine today, however research in this area and the translation to clinic is largely focused on biologicals such as monoclonal antibodies, cell therapy, etc. Small molecules modulators of the immune system have the potential to overcome challenges faced by biological drugs and also complement them for improving treatment efficacy. The goal of this special issue would be to bring attention to the latest advances in small molecule modulators of the immune system for treatment of cancer and infectious diseases.
We welcome Original Research, Review, Mini Review and Perspective articles on themes including, but not limited to:
• Discovery and design of novel small molecules and peptides
• Lead optimization and structure-activity relationship studies
• Applications of small molecule and peptide based therapeutics for immunotherapy of cancer
• Chemical probes and chemical biology studies for new targets in immunotherapy
Topic Editor Dr. Aditya Kulkarni is the founder and CSO of Avammune Therapeutics and Aten Porus Lifesciences. Topic editor Dr. Madduri Srinivasarao is currently serving as the Vice President of R&D at Eradivir, Inc. and serves as a consultant at Morphimmune Inc. and Umoja Biopharma Inc. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation are considered out of scope of this section.
